gemfibrozil has been researched along with Body Weight in 23 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10." | 9.24 | Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017) |
| "The Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) showed that gemfibrozil significantly reduced major coronary events in men with known coronary heart disease (CHD)." | 9.13 | Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). ( Bloomfield, HE; Collins, D; McNamara, JR; Robins, SJ, 2008) |
| "In a double-blind, randomized crossover study, 29 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipoproteinemia were treated with gemfibrozil (1,200 mg/d) or simvastatin (10 mg/d) for 4 months." | 9.08 | A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. ( Johansson, J; Lithell, H; Ohrvall, M; Vessby, B, 1995) |
| "Mixed hyperlipidemia is a common risk factor for cardiovascular disease." | 6.70 | Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. ( Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L, 2001) |
| " After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10." | 5.24 | Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017) |
| "The Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) showed that gemfibrozil significantly reduced major coronary events in men with known coronary heart disease (CHD)." | 5.13 | Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). ( Bloomfield, HE; Collins, D; McNamara, JR; Robins, SJ, 2008) |
| "In a double-blind, randomized crossover study, 29 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipoproteinemia were treated with gemfibrozil (1,200 mg/d) or simvastatin (10 mg/d) for 4 months." | 5.08 | A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. ( Johansson, J; Lithell, H; Ohrvall, M; Vessby, B, 1995) |
| "Gemfibrozil is a PPAR-α ligand that inhibits the progression of atherosclerosis in insulin resistance type 2 diabetes mellitus (IR type 2 DM)." | 3.79 | Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats. ( Kurmi, MK; Raikwar, SK; Sharma, AK; Srinivasan, BP, 2013) |
| "A retrospective chart analysis of 200 consecutive, cyclosporine-treated, renal allograft recipients, transplanted between January 1988 and June 1992, was conducted to determine the incidence of and the etiologic variables for post-transplant hypercholesterolemia." | 3.69 | Post-transplant hyperlipidemia: risk factors and response to dietary modification and gemfibrozil therapy. ( Aridge, D; Bastani, B; Garvin, PJ; Heisler, T; Lindsey, L; Puntney, G; Robinson, S; Solomon, H, 1995) |
| "Mixed hyperlipidemia is a common risk factor for cardiovascular disease." | 2.70 | Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. ( Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L, 2001) |
| "Thirteen patients with phenotypic type V hyperlipidemia were treated with either gemfibrozil (Lopid) or a placebo in a randomized, double-blind, crossover study for two 8-week periods." | 2.66 | The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. ( Bacon, SP; Connor, WE; Illingworth, DR; Leaf, DA; Sexton, G, 1989) |
| "In Ppara-null mice, MFD treatment increased body weight, adipose tissue, serum TG and impaired glucose tolerance." | 1.48 | PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling. ( Dai, M; Gonzalez, FJ; Hua, H; Huang, J; Lin, H; Liu, A; Liu, L; Wang, F; Xi, Y; Xu, G; Yang, J; Zhao, T, 2018) |
| "Gemfibrozil treatment had no effect on blood glucose, plasma insulin and vessel antioxidant enzyme activity of diabetic animals." | 1.31 | Short-term gemfibrozil treatment reverses lipid profile and peroxidation but does not alter blood glucose and tissue antioxidant enzymes in chronically diabetic rats. ( Akin, B; Aktan, F; Karasu, C; Ozansoy, G, 2001) |
| "Treatment with gemfibrozil modifies acyl composition of hepatic microsomal phosphatidylcholine and phosphatidylethanolamine in guinea-pigs." | 1.29 | Gemfibrozil modifies acyl composition of liver microsomal phospholipids from guinea-pigs without promoting peroxisomal proliferation. ( Adzet, T; Alegret, M; Laguna, JC; Merlos, M; Vázquez, M, 1993) |
| "Terbutaline has also been reported to raise HDL cholesterol." | 1.27 | Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis. ( Glueck, CJ, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (30.43) | 18.7374 |
| 1990's | 8 (34.78) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hussain, M | 1 |
| Shad, MN | 1 |
| Akhtar, L | 1 |
| Hua, H | 1 |
| Yang, J | 1 |
| Lin, H | 1 |
| Xi, Y | 1 |
| Dai, M | 1 |
| Xu, G | 1 |
| Wang, F | 1 |
| Liu, L | 1 |
| Zhao, T | 1 |
| Huang, J | 1 |
| Gonzalez, FJ | 1 |
| Liu, A | 1 |
| Sharma, AK | 1 |
| Raikwar, SK | 1 |
| Kurmi, MK | 1 |
| Srinivasan, BP | 1 |
| Sanguino, E | 1 |
| Roglans, N | 1 |
| Alegret, M | 2 |
| Sánchez, RM | 1 |
| Vázquez-Carrera, M | 1 |
| Laguna, JC | 2 |
| Mimeault, C | 1 |
| Trudeau, VL | 1 |
| Moon, TW | 1 |
| Robins, SJ | 1 |
| Collins, D | 1 |
| McNamara, JR | 1 |
| Bloomfield, HE | 1 |
| Torstila, I | 1 |
| Kaukola, S | 1 |
| Manninen, V | 1 |
| Virtamo, J | 1 |
| Mälkönen, M | 1 |
| Fitzgerald, JE | 2 |
| Sanyer, JL | 1 |
| Schardein, JL | 1 |
| Lake, RS | 1 |
| McGuire, EJ | 1 |
| de la Iglesia, FA | 2 |
| Scarano, LJ | 1 |
| Calabrese, EJ | 1 |
| Kostecki, PT | 1 |
| Baldwin, LA | 1 |
| Leonard, DA | 1 |
| Bastani, B | 1 |
| Robinson, S | 1 |
| Heisler, T | 1 |
| Puntney, G | 1 |
| Aridge, D | 1 |
| Lindsey, L | 1 |
| Solomon, H | 1 |
| Garvin, PJ | 1 |
| Hashimoto, F | 1 |
| Ishikawa, T | 1 |
| Hamada, S | 1 |
| Hayashi, H | 1 |
| Ohrvall, M | 1 |
| Lithell, H | 1 |
| Johansson, J | 1 |
| Vessby, B | 1 |
| Donnelly, R | 1 |
| Plato, PA | 1 |
| Chang, H | 1 |
| Reaven, GM | 1 |
| Vázquez, M | 1 |
| Adzet, T | 1 |
| Merlos, M | 1 |
| Hofstra, AH | 1 |
| King, LM | 1 |
| Walker, RM | 1 |
| Krause, BR | 1 |
| Barnett, BC | 1 |
| Essenburg, AD | 1 |
| Kieft, KA | 1 |
| Auerbach, BJ | 1 |
| Bousley, R | 1 |
| Stanfield, R | 1 |
| Newton, RS | 1 |
| Bisgaier, CL | 1 |
| Ozansoy, G | 1 |
| Akin, B | 1 |
| Aktan, F | 1 |
| Karasu, C | 1 |
| Aguilar-Salinas, CA | 1 |
| Fanghänel-Salmón, G | 1 |
| Meza, E | 1 |
| Montes, J | 1 |
| Gulías-Herrero, A | 1 |
| Sánchez, L | 1 |
| Monterrubio-Flores, EA | 1 |
| González-Valdez, H | 1 |
| Gómez Pérez, FJ | 1 |
| Leaf, DA | 1 |
| Connor, WE | 1 |
| Illingworth, DR | 1 |
| Bacon, SP | 1 |
| Sexton, G | 1 |
| Glueck, CJ | 1 |
| Petrere, JA | 1 |
| Leiss, O | 1 |
| von Bergmann, K | 1 |
| Gnasso, A | 1 |
| Augustin, J | 1 |
6 trials available for gemfibrozil and Body Weight
| Article | Year |
|---|---|
Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia.
Topics: Adult; Aged; Body Mass Index; Body Weight; Dyslipidemias; Female; Gemfibrozil; Humans; Hypoglycemic | 2017 |
Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT).
Topics: Aged; Body Weight; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; In | 2008 |
Plasma prekallikrein, kallikrein inhibitors, kininogen and lipids during gemfibrozil treatment in type II dyslipidaemia.
Topics: Adult; Aprotinin; Body Weight; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Female; Gemf | 1982 |
A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.
Topics: Aged; Body Weight; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Gemfibroz | 1995 |
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, | 2001 |
The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study.
Topics: Adult; Aged; Body Weight; Cholesterol, VLDL; Clinical Protocols; Clinical Trials as Topic; Double-Bl | 1989 |
17 other studies available for gemfibrozil and Body Weight
| Article | Year |
|---|---|
PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Body Weight; Fenofibrate; Fibric Acids; Gemfibrozil; Glucose | 2018 |
Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats.
Topics: Adiponectin; Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug | 2013 |
Different response of senescent female Sprague-Dawley rats to gemfibrozil and rosiglitazone administration.
Topics: Adipose Tissue; Aging; Animals; Blood Glucose; Body Weight; Cholesterol; Diet; DNA-Binding Proteins; | 2005 |
Waterborne gemfibrozil challenges the hepatic antioxidant defense system and down-regulates peroxisome proliferator-activated receptor beta (PPARbeta) mRNA levels in male goldfish (Carassius auratus).
Topics: Actins; Acyl-CoA Oxidase; Animals; Antioxidants; Body Weight; Cytochrome P-450 CYP1A1; Down-Regulati | 2006 |
Consensus conference: Treatment of hypertriglyceridemia.
Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipopro | 1984 |
Carcinogen bioassay and mutagenicity studies with the hypolipidemic agent gemfibrozil.
Topics: Animals; Biotransformation; Body Weight; Carcinogens; Female; Gemfibrozil; Hypolipidemic Agents; Liv | 1981 |
Evaluation of a rodent peroxisome proliferator in two species of freshwater fish: rainbow trout (Onchorynchus mykiss) and Japanese medaka (Oryzias latipes)
Topics: Animals; Body Weight; Female; Gemfibrozil; Injections, Intraperitoneal; Liver; Male; Microbodies; On | 1994 |
Post-transplant hyperlipidemia: risk factors and response to dietary modification and gemfibrozil therapy.
Topics: Adult; Age Factors; Black People; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Cholester | 1995 |
Effect of gemfibrozil on lipid biosynthesis from acetyl-CoA derived from peroxisomal beta-oxidation.
Topics: Animals; Bile Acids and Salts; Body Weight; Cholesterol; Fatty Acids; Gemfibrozil; Hydroxymethylglut | 1995 |
Effects of gemfibrozil on triglyceride metabolism in Dahl salt-sensitive rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Gemfibrozil; Insulin; Lipoprotein Lipase; Lipop | 1994 |
Gemfibrozil modifies acyl composition of liver microsomal phospholipids from guinea-pigs without promoting peroxisomal proliferation.
Topics: Animals; Body Weight; Fatty Acids; Gemfibrozil; Guinea Pigs; Microbodies; Microsomes, Liver; Organ S | 1993 |
Peroxisome proliferation and microsomal enzyme induction by the hypolipidemic CI-924 in rats and mice: relationship to tumorgenicity.
Topics: Animals; Blotting, Western; Body Weight; Carcinogenicity Tests; Carcinogens; Electrophoresis, Polyac | 1995 |
Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats.
Topics: Animals; Apolipoproteins B; Apolipoproteins E; Bezafibrate; Body Weight; Cholesterol; Cholesterol, L | 1996 |
Short-term gemfibrozil treatment reverses lipid profile and peroxidation but does not alter blood glucose and tissue antioxidant enzymes in chronically diabetic rats.
Topics: Animals; Antioxidants; Aorta; Blood Glucose; Body Weight; Catalase; Cholesterol; Diabetes Mellitus, | 2001 |
Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Arteriosclerosis; Body Weight; Cholesterol, H | 1985 |
Experimental studies on reproduction with the lipid-regulating agent gemfibrozil.
Topics: Animals; Body Weight; Eating; Female; Fertility; Fetus; Gemfibrozil; Hypolipidemic Agents; Male; Pen | 1987 |
Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects.
Topics: Adult; Bile; Bile Acids and Salts; Biliary Tract; Body Weight; Cholesterol; Cholesterol, HDL; Duoden | 1985 |